Impact of CACNA1C polymorphisms on antihypertensive efficacy of calcium channel blocker

Chinese Journal of Cardiology

Volumn 40, Issue 1, 2012, Pages 3-7

  Sun, Qian ^a   Li, Qing Xian ^a   Song, Xi Fa ^b   Zheng, Song Gui ^b   Yan, Feng ^a   Chen, Peng ^b   Tang, Ji Fei ^b   Niu, Yu Xin ^b   Bao, Qi Yu ^b   Zhang, Guo Qiang ^b   Hu, Yun Liang ^a  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

Calcium channel blockers; Hypertension; Polymorphism,single nucleotide

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE A1 C; NIFEDIPINE; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CHINESE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; ESSENTIAL HYPERTENSION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MONOTHERAPY; MULTIPLEX POLYMERASE CHAIN REACTION; PHARMACOGENETICS; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84861312856     PISSN: 02533758     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3758.2012.01.002     Document Type: Article

References (11)

1. Mori H, Ukai H, Yamamoto H, et al. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res, 2006, 29: 143-151.
2. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension, 2004, 44: 398-404.
3. Kurland L, Liljedahl U, Lind L. Hypertension and SNP genotyping in antihypertensive treatment. Cardiovasc Toxicol, 2005, 5: 133-142.
4. Marteau JB, Zaiou M, Siest G, et al. Genetic determinants of blood pressure regulation. J Hypertens, 2005, 23: 2127-2143.
5. Kojima T, Miyauchi K, Yokoyama T, et al. Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J). Circ J, 2011, 75: 1071-1079.
6. Rothwell PM, Howard SC, Dolan E, et al. Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol, 2010, 9: 469-480.
7. Soldatov NM. Genomic structure of human L-type Ca2 + channel. Genomics, 1994, 22: 77-87.
8. Wang D, Papp AC, Binkley PF, et al. Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues. Pharmacogenet Genomics, 2006, 16: 735-745.
9. Tang ZZ, Liang MC, Lu S, et al. Transcript scanning reveals novel and extensive splice variations in human l-type voltage-gated calcium channel, Cav1.2 alphal subunit. J Biol Chem, 2004, 279: 44335-44343.
10. Kamide K, Yang J, Matayoshi T, et al. Genetic polymorphisms of L-type calcium channel αlc and α1D subunit genes are associated with sensitivity to the antihypertensive effects of L-type dihydropyri calcium-channel blockers. Circ J, 2009, 73: 732-740.
11. Beitelshees AL, Navare H, Wang D, et al. CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet, 2009, 2: 362-370.